Clinical research has demonstrated that brain reserve (BR) could exert positive effects on cognition for patients with Alzheimer’s disease (AD) and mild cognitive impairment (MCI). However, the effects of BR on cognition in individuals with subjective cognitive decline (SCD) are not clear.
Objective:
To examine cross-sectional effects of BR on cognition in SCD populations.
Methods:
One hundred forty-nine subjects were studied from the Sino Longitudinal Study on Cognitive Decline (SILCODE) study. Head circumference was used as a proxy of BR. Cognition was assessed across four domains (memory, executive, language, and general cognitive functions). Multiple linear regression models were conducted to examine effects of BR on cognitive scores. Furthermore, we addressed the question that whether the degree of self-perception of cognitive decline modified the effect of BR on cognitive performance in SCD subjects.
Results:
We found a positive effect of BR on language cognition in subjects with SCD. Furthermore, the positive effect of BR on language cognition survived in SCD participants with a low degree of self-perception of cognitive decline while disappeared in SCD participants with a high degree of self-perception of cognitive decline.
Conclusion:
This study suggests that BR has the potential to delay or slow down cognitive decline in SCD individuals, especially for mild SCD.
Alzheimer’s Association (2019) 2019 Alzheimer’s disease facts and figures. Alzheimers Dement15, 321–387.
2.
MontineTJ, PhelpsCH, BeachTG, BigioEH, CairnsNJ, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, TrojanowskiJQ, VintersHV, HymanBT (2012) National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol123, 1–11.
3.
JackCJ, KnopmanDS, JagustWJ, ShawLM, AisenPS, WeinerMW, PetersenRC, TrojanowskiJQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol9, 119–128.
4.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCJ, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
5.
VisserPJ, TijmsB (2017) Brain amyloid pathology and cognitive function: Alzheimer disease without dementia?JAMA317, 2285–2287.
KatzmanR, TerryR, DeTeresaR, BrownT, DaviesP, FuldP, RenbingX, PeckA (1988) Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol23, 138–144.
BorensteinGA, MortimerJA, BowenJD, McCormickWC, McCurrySM, SchellenbergGD, LarsonEB (2001) Head circumference and incident Alzheimer’s disease: Modification by apolipoprotein E. Neurology57, 1453–1460.
14.
KimJ, StewartR, ShinI, KimS, YangS, YoonJ (2008) Associations between head circumference, leg length and dementia in a Korean population. Int J Geriatr Psychiatry23, 41–48.
15.
GrootC, van LoenhoudAC, BarkhofF, van BerckelBNM, KoeneT, TeunissenCC, ScheltensP, van der FlierWM, OssenkoppeleR (2018) Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology90, e149–e156.
16.
GuoL, AlexopoulosP, WagenpfeilS, KurzA, PerneczkyR (2013) Brain size and the compensation of Alzheimer’s disease symptoms: A longitudinal cohort study. Alzheimers Dement9, 580–586.
17.
PerneczkyR, AlexopoulosP, WagenpfeilS, BickelH, KurzA (2012) Head circumference, apolipoprotein E genotype and cognition in the Bavarian School Sisters Study. Eur Psychiatry27, 219–222.
18.
PerneczkyR, WagenpfeilS, LunettaKL, CupplesLA, GreenRC, DecarliC, FarrerLA, KurzA (2010) Head circumference, atrophy, and cognition: Implications for brain reserve in Alzheimer disease. Neurology75, 137–142.
19.
JessenF, AmariglioRE, van BoxtelM, BretelerM, CeccaldiM, ChetelatG, DuboisB, DufouilC, EllisKA, van der FlierWM, GlodzikL, van HartenAC, de LeonMJ, McHughP, MielkeMM, MolinuevoJL, MosconiL, OsorioRS, PerrotinA, PetersenRC, RabinLA, RamiL, ReisbergB, RentzDM, SachdevPS, de la SayetteV, SaykinAJ, ScheltensP, ShulmanMB, SlavinMJ, SperlingRA, StewartR, UspenskayaO, VellasB, VisserPJ, WagnerM (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement10, 844–852.
20.
RabinLA, SmartCM, AmariglioRE (2017) Subjective cognitive decline in preclinical Alzheimer’s disease. Annu Rev Clin Psychol13, 369–396.
21.
MolinuevoJL, RabinLA, AmariglioR, BuckleyR, DuboisB, EllisKA, EwersM, HampelH, KlöppelS, RamiL, ReisbergB, SaykinAJ, SikkesS, SmartCM, SnitzBE, SperlingR, van der FlierWM, WagnerM, JessenF (2017) Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement13, 296–311.
22.
LiX, WangX, SuL, HuX, HanY (2019) Sino Longitudinal Study on Cognitive Decline (SILCODE): Protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive impairment in individuals with subjective cognitive decline. BMJ Open9, e028188.
23.
ChenG, YangK, DuW, HuX, HanY (2019) Clinical characteristics in subjective cognitive decline with and without worry: Baseline investigation of the SILCODE Study. J Alzheimers Dis72, 443–454.
24.
GiffordKA, LiuD, RomanoRR, JonesRN, JeffersonAL (2015) Development of a subjective cognitive decline questionnaire using item response theory: A pilot study. Alzheimers Dement (Amst)1, 429–439.
25.
HamiltonM (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry23, 56–62.
26.
HamiltonM (1959) The assessment of anxiety states by rating. Br J Med Psychol32, 50–55.
27.
GuoQ, SunY, YuP, HongZ, LvC (2007) Norm of Auditory Verbal Learning Test in the normal aged in China community. Chin J Clin Psychol15, 132–134.
28.
ZhaoQ, GuoQ, LiF, ZhouY, WangB, HongZ (2013) The Shape Trail Test: Application of a new variant of the Trail making test. PLoS One8, e57333.
29.
ZhaoQ, GuoQ, HongZ (2013) Clustering and switching during a semantic verbal fluency test contribute to differential diagnosis of cognitive impairment. Neurosci Bull29, 75–82.
30.
KaplanE, GoodglassH, WeintraubS (1983) Boston Naming Test, Philadelphia Lea & Febiger.
31.
ChenKL, XuY, ChuAQ, DingD, LiangXN, NasreddineZS, DongQ, HongZ, ZhaoQH, GuoQH (2016) Validation of the Chinese version of Montreal Cognitive Assessment Basic for screening mild cognitive impairment. J Am Geriatr Soc64, e285–e290.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
